AzTrials
AzTrials

TraumaPhase 2KetNCT03233035

Low Dose Ketamine Intra Nasal Traumatology

A Phase 2 study testing Ketamine in people with Trauma, run by University of Monastir at 2 sites in Tunisia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or non opioids analgesic agents. Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Trauma
What is being tested?
Ketamine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
1,102 participants
Where
2 sitesTunisia
Study dates
1 Jan 2018to 1 Dec 2018
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analgesic scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.

Who cannot join

  • - Pregnancy,
  • Breast-feeding,
  • Altered mental status,
  • Allergy to ketamine or morphine or
  • Weight less than 46 kg or greater than 115 kg,
  • Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
Show all 10Show fewer
  • Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
  • Alcohol or drug abuse,
  • Psychiatric illness,
  • Recent (4 hours before) analgesic agent use.

Trial locations and contacts

2 sites in 1 country.

Tunisia2 sites
  • Nouira Samir

    Monastir, Emergency Department Monastir, Tunisia 5000, 5000

  • Emergency department of university hospital Fattouma Bourguiba of Monastir

    Monastir, 5000

Other trials in Tunisia

About this study

Official title: Intranasal Ketamine for Treatment of Acute Pain in the Emergency Department : A Randomized Controlled Trial

To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or non opioids analgesic agents.

Read the detailed description

Intranasal ketamine for treatment of acute pain in the emergency department : A randomized controlled trial

Introduction :

Pain is the most common complaint for emergency department (ED) visits [1].The provision of adequate, safe, and timely analgesia is a core component of patient care in the emergency department (ED). Ketamine is a noncompetitive Nmethyl- D-aspartate and glutamate receptor antagonist that decreases central sensitization, "wind-up" phenomena, and pain memory [2,3].

At subdissociative doses (0.1 to 0.6 mg/kg; most commonly 0.3 mg/kg) maintains potent analgesic and amnestic effects that are accompanied by preservation of protective airway reflexes, spontaneous respiration, and cardiopulmonary stability [4-6].

Intranasal route ….

Objective of the study :

To evaluate the efficacy and safety of early administration of low-dose intranasal ketamine analgesic agents in patients with moderate to severe pain in the ED in reducing the need for opioid or class III analgesic agents.

Materials and Methods :

Study design :

It is a ramdomized, prospective, double blind, controlled, multicentric trial. The study is registered with clinical.tria.gov (…….).

Study Setting and Selection of Participants :

The trial is conducted in three community teaching hospitals :

  • Emergency department, fattouma bourguiba university hospital, monastir, tunisia
  • Emergency department, sahloul university hospital, sousse, tunisia
  • Emergency department, farhat hached university hospital, sousse, tunisia

ED principal investigators maintain the randomization list, which is generated before the start of the study, prepare the medication, and deliver it to the treating physician in a blinded manner.

Inclusion criteria :

The study includes patients aged 18 to 80 years who presented to the ED with acute limb trauma pain with a visual analogue scale (VAS) of 5 or more on a standard 11- point (0 to 10). An informed consent is necessary.

Exclusion criteria :

  • Pregnancy,
  • Breast-feeding,
  • Altered mental status,
  • Allergy to ketamine or morphine or
  • Weight less than 46 kg or greater than 115 kg,
  • Unstable vital signs (systolic blood pressure <90 or >180 mm Hg, pulse rate <50 or >150 beats/min, and respiration rate <10 or >30 breaths/min),
  • Medical history of acute head or eye injury, seizure, intracranial hypertension, chronic pain, severre renal or hepatic insufficiency,
  • Alcohol or drug abuse,
  • Psychiatric illness,
  • Recent (4 hours before) analgesic agent use.

Protocol :

In the triage area, each patient having the inclusion criteria receives 25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril or 0.5 mL of normal saline solution in one pulverisation per nostril as a placebo according to the predetermined randomization list. None of the treating physician or nurses is aware about the medication received. In all patients included, the investigators collect vital signs ; demographic and clinical data.

Study investigators record VAS, and adverse effects at 15, 30, 60, 90, and 120 minutes.

At 30 minutes, if patients report a pain numeric rating scale score of 5 or greater and request additional pain relief, titrated morphine is administered as a rescue analgesic with a dose of 0.1 mg/Kg repeated every 3 to 5 minutes if the pain numeric rating scale score is still greater or equal to 3.

All data recorded on data collection sheets, including sex, demographics, medical history, and vital signs, were entered into SPSS (version 20.0; IBM Corp) by the research manager.

Patients's informed consent is obtained. The ethic commitee of our institution approved the study.

Endpoints :

Primary endpoints :

  • Need for rescue opioids during ED stay

Secondary endpoints :

  • requirement of non-opioids analgesic agents.
  • percentage of patients discharged from the ED with VAS <30.
  • Safety : adverse events
Conditions
Trauma
Being tested
Ketamine, Placebo
Keywords
Ketamine-Intranasal-Acute pain-Emergency departement
Medical subject headings
Wounds and Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • KetamineDrug

    25mg of ketamine in 0.5 ml of serum saline in one pulverisation per nostril is received

  • PlaceboDrug

    Also called normal saline solution

    0.5 mL of normal saline solution as a placebo in one pulverisation per nostril

Study groups in NCT03233035
Study groupRoleWhat they receive
placebo groupPlacebo comparatorIntranasal placebo pulverisation
Receives: Drug: Placebo
Ketamine groupActive comparatorIntranasal ketamine pulverisation
Receives: Drug: Ketamine

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Number and percentage of patients who need rescue opiods in the two groups

    the need for rescue opioids during ED stay

    Measured: 30 minutes

Secondary outcomes (3)
  1. Intolerance to treatement and adverse events

    Noticing any sign of intolerance due to treatement : Dizziness , Vomiting..

    Measured: 30 minutes and at 120 minutes

  2. Percentage of patients with VAS <30 mm at discharge

    percentage of patients discharged from the ED with VAS <30.

    Measured: 120 minutes

  3. Number and percentage of patients who required non opiods analgesics

    Requirement of non-opioids analgesic agents

    Measured: 30 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Jul 2017
  2. Study start1 Jan 2018
  3. Primary completion1 Dec 2018
  4. Study completion1 Dec 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double Blind Study
Masking
Triple blind
Who is masked
Participant, Care provider, Investigator
Enrolment
1,102 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03233035
Sponsor's protocol ID
Ket-Int-Nas-TR
Acronym
Ket
Status last verified
Jun 2019
First submitted
14 May 2017
Last updated
2 Jul 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Ketamine in people with Trauma, run by University of Monastir at 2 sites in Tunisia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 2 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Tunisia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Number and percentage of patients who need rescue opiods in the two groups (time frame: 30 minutes). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in